Fundraising FoxRenovion
Durham, US · Founded 2013 · North Carolina corporation · 1 known investors
Find your way into Renovion
Sign up to see every warm intro you have to Renovion
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renovion team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Renovion develops ARINA-1, a next-generation mucolytic therapy delivered as a sterile buffered ascorbic acid and glutathione solution to the lungs. The therapy targets chronic inflammatory airway diseases affecting over 170 million patients globally, including non-cystic fibrosis bronchiectasis, chronic bronchitis, COPD, and asthma.
Founders & leadership
DW
Daniel W. CopelandExecutive
Board
RF
R. Frederick McCoy, Jr.Board director
JD
Joseph DavisBoard director
DW
Derek WinstanlyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$25.8M disclosed across 5 rounds · 2016–2022
▶$15MraisedMar 2023 · 24 investors · PharmaceuticalsRule 506(b)
▶$15MraisedMar 2023 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- THOMAS U. BARTONDirector
- DEREK WINSTANLYDirector
- RICHARD MATTINGLYDirector
- DANIEL W. COPELANDExecutive Officer, Director
- JON CIVITARESEDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2022
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$8.1MraisedMay 2020 · 43 investors · PharmaceuticalsRule 506(b)
▶$8.1MraisedMay 2020 · 43 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- THOMAS U. BARTONDirector
- DEREK WINSTANLYDirector
- DANIEL W. COPELANDExecutive Officer, Director
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- First sale
- Feb 2020
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$492.2KraisedFeb 2019 · 10 investors · PharmaceuticalsRule 506(b)
▶$492.2KraisedFeb 2019 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- R. FREDERICK MCCOY, JR.Director
- DANIEL W. COPELANDExecutive Officer, Director
- DEREK WINSTANLYDirector
- ROBERT RYANDirector
- Offering amount
- $800K
- Amount sold
- $492.2K
- First sale
- Jan 2019
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$350KraisedMay 2018 · 12 investors · PharmaceuticalsRule 506(b)
▶$350KraisedMay 2018 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert RyanDirector
- Daniel W. CopelandExecutive Officer, Director
- R. Frederick McCoy, Jr.Director
- Derek WinstanlyDirector
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- May 2018
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
▶$1.9MraisedJan 2017 · 13 investors · PharmaceuticalsRule 506(b)
▶$1.9MraisedJan 2017 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- R. Frederick McCoy, Jr.Director
- Joseph DavisDirector
- Derek WinstanlyDirector
- Daniel W. CopelandExecutive Officer, Director
- Offering amount
- $2.1M
- Amount sold
- $1.9M
- First sale
- Aug 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
Companies working in the same space as Renovion.
Frequently asked questions
- What does Renovion do?
- Renovion develops ARINA-1, a next-generation mucolytic therapy delivered as a sterile buffered ascorbic acid and glutathione solution to the lungs. The therapy targets chronic inflammatory airway diseases affecting over 170 million patients globally, including non-cystic fibrosis bronchiectasis, chronic bronchitis, COPD, and asthma.
- Who are Renovion's investors?
- Renovion's investors include Texas HALO Fund.
- How much funding has Renovion raised?
- Renovion has disclosed $25.8M raised across 5 rounds.
- Where is Renovion headquartered?
- Renovion is headquartered in Durham, US.